European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology

January 4, 2024

https://www.globenewswire.com/news-release/2024/01/04/2803932/0/en/European-Patent-Office-Approves-Key-Patent-for-Indaptus-Therapeutics-Platform-Technology.html

NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc. (Nasdaq:INDP), a clinical stage biopharma company that utilizes a proprietary killed, non-pathogenic bacteria-based platform to generate stabilized packages of immune agonists to activate both innate (immediate) and adaptive (learned) cellular immune pathways, announces that the European Patent Office (EPO) has informed the company that it will grant a European patent related to the company’s platform technology, covering a composition that can be used in the prevention or treatment of viral infections.

Read more at globenewswire.com

Related news for (INDP)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.